Mobile app version of munafa.co.com
Login or Join
 Learn then Earn
stockMarketNEWS

 story : Pfizer submits a new NDA to FDA for COVID-19 pill PAXLOVID #FinanceUSA #StockMarketNEWS Pfizer Inc. said Thursday that it has submitted a New Drug Application (NDA) for COVID-19 treatment pills PAXLOVID

@stockMarketNEWS Fri 01 Jul, 2022

Posted in: #FinanceUSA #StockMarketNEWS

Pfizer submits a new NDA to FDA for COVID-19 pill PAXLOVID #FinanceUSA #StockMarketNEWS
Pfizer Inc. said Thursday that it has submitted a New Drug Application (NDA) for COVID-19 treatment pills PAXLOVID for patients at high risk for progression to severe illness. PAXLOVID has previously been granted Emergency Use Authorization (EUA) for treatment of mild-to-moderate COVID-19. The drug maker said the NDA submission provides longer-term follow-up data needed for potential approval. "Data from our clinical development program, coupled with the more than 1.7 million patients around the world who have been prescribed our oral treatment to date, reinforce PAXLOVID as an important treatment option for mild-to-moderate COVID-19 in patients at greater risk of progression to severe symptoms, regardless of vaccination status," said Pfizer Chief Executive Albert Bourla. The stock, which slipped 0.6% in premarket trading, has lost 13.7% year to date through Wednesday, while the S&P 500 has climbed 19.9%.


Munafa USA Munafa India Munafa NSE


Report

Login to follow story

More posts by @stockMarketNEWS

Munafa ebook, learn stock market trading

0 Comments

Sorted by latest first Latest Oldest Best

Daily analysis, news, Munafa stocks list in email:

Back to top | Use Dark Theme